Regeneron Pharmaceuticals’ (REGN) Hold Rating Reiterated at Cowen

Regeneron Pharmaceuticals (NASDAQ:REGN)‘s stock had its “hold” rating reiterated by equities researchers at Cowen in a research report issued to clients and investors on Wednesday. They currently have a $450.00 target price on the biopharmaceutical company’s stock. Cowen’s price objective indicates a potential upside of 34.48% from the company’s previous close.

Other analysts also recently issued reports about the company. BTIG Research restated a “buy” rating and issued a $520.00 price objective on shares of Regeneron Pharmaceuticals in a report on Wednesday, November 22nd. Canaccord Genuity restated a “buy” rating and issued a $522.00 price objective on shares of Regeneron Pharmaceuticals in a report on Wednesday. BMO Capital Markets set a $444.00 price objective on Regeneron Pharmaceuticals and gave the company a “hold” rating in a report on Monday, November 27th. Citigroup downgraded Regeneron Pharmaceuticals from a “buy” rating to a “neutral” rating and decreased their price objective for the company from $480.00 to $380.00 in a report on Friday, December 1st. Finally, Piper Jaffray Companies restated a “buy” rating and issued a $540.00 price objective on shares of Regeneron Pharmaceuticals in a report on Monday, November 13th. Four investment analysts have rated the stock with a sell rating, fourteen have issued a hold rating and eleven have given a buy rating to the stock. Regeneron Pharmaceuticals presently has an average rating of “Hold” and a consensus target price of $470.84.

Regeneron Pharmaceuticals (NASDAQ:REGN) traded down $4.19 during midday trading on Wednesday, reaching $334.61. The company had a trading volume of 985,317 shares, compared to its average volume of 978,731. The firm has a market capitalization of $36,010.00, a P/E ratio of 30.39, a price-to-earnings-growth ratio of 1.25 and a beta of 1.47. Regeneron Pharmaceuticals has a 1-year low of $319.50 and a 1-year high of $543.55. The company has a quick ratio of 3.07, a current ratio of 3.63 and a debt-to-equity ratio of 0.12.

Several hedge funds have recently added to or reduced their stakes in the company. LS Investment Advisors LLC boosted its position in shares of Regeneron Pharmaceuticals by 17.0% during the 4th quarter. LS Investment Advisors LLC now owns 2,465 shares of the biopharmaceutical company’s stock worth $927,000 after purchasing an additional 358 shares in the last quarter. California Public Employees Retirement System boosted its position in shares of Regeneron Pharmaceuticals by 6.3% during the 4th quarter. California Public Employees Retirement System now owns 184,939 shares of the biopharmaceutical company’s stock worth $69,530,000 after purchasing an additional 10,910 shares in the last quarter. AE Wealth Management LLC bought a new position in shares of Regeneron Pharmaceuticals during the 4th quarter worth about $206,000. BT Investment Management Ltd boosted its position in shares of Regeneron Pharmaceuticals by 6,246.3% during the 4th quarter. BT Investment Management Ltd now owns 9,456 shares of the biopharmaceutical company’s stock worth $3,555,000 after purchasing an additional 9,307 shares in the last quarter. Finally, Mitsubishi UFJ Kokusai Asset Management Co. Ltd. boosted its position in shares of Regeneron Pharmaceuticals by 3.3% during the 4th quarter. Mitsubishi UFJ Kokusai Asset Management Co. Ltd. now owns 14,278 shares of the biopharmaceutical company’s stock worth $5,622,000 after purchasing an additional 450 shares in the last quarter. 65.69% of the stock is currently owned by institutional investors.

COPYRIGHT VIOLATION NOTICE: “Regeneron Pharmaceuticals’ (REGN) Hold Rating Reiterated at Cowen” was originally published by Community Financial News and is the sole property of of Community Financial News. If you are reading this news story on another publication, it was copied illegally and republished in violation of international trademark & copyright legislation. The legal version of this news story can be viewed at https://www.com-unik.info/2018/02/07/regeneron-pharmaceuticals-regn-hold-rating-reiterated-at-cowen.html.

Regeneron Pharmaceuticals Company Profile

Regeneron Pharmaceuticals, Inc is a biopharmaceutical company that discovers, invents, develops, manufactures and commercializes medicines for the treatment of serious medical conditions. The Company commercializes medicines for eye diseases, high low-density lipoprotein (LDL) cholesterol, and an inflammatory condition and have product candidates in development in other areas, including rheumatoid arthritis, asthma, atopic dermatitis, pain, cancer, and infectious diseases.

Analyst Recommendations for Regeneron Pharmaceuticals (NASDAQ:REGN)

Receive News & Ratings for Regeneron Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Regeneron Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.

Comments

Leave a Reply


share news on Facebook
tweet this investment news
share on linkedin
share on StockTwits
share on Google Plus
share on reddit